Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, June 2016

Altmetric Badge

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 14 Mendeley

Summary Dimensions citations

So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom

Article in Microbiology Spectrum (May 2022)

Budget Impact of Microbial Cell-Free DNA Testing Using the Karius® Test as an Alternative to Invasive Procedures in Immunocompromised Patients with Suspected Invasive Fungal Infections

Article in Applied Health Economics and Health Policy (September 2020)

Cost‐effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant

Article in Transplant Infectious Disease (August 2019)